TOPICAL CORTICOSTEROIDS AND UNWANTED LOCAL-EFFECTS - IMPROVING THE BENEFIT RISK RATIO

被引：30

作者：

MORI, M ^{[1
]}

PIMPINELLI, N ^{[1
]}

GIANNOTTI, B ^{[1
]}

机构：

[1] UNIV FLORENCE,DERMATOL CLIN 2,VIA PERGOLA 58,I-50121 FLORENCE,ITALY

来源：

DRUG SAFETY | 1994年 / 10卷 / 05期

关键词：

D O I：

10.2165/00002018-199410050-00005

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

The main goal of pharmacological research in the field of topical corticosteroids (TCs) is to dissociate efficacy and adverse effects as much as possible. The optimal use of TCs, i.e. the careful evaluation of the benefit/risk ratio, depends on: (i) the chemical structure of the TC; (ii) the type of vehicle, (iii) the mode of application; and (iv) the features of the skin to be treated. The recent availability of TCs characterised by a good dissociation between efficacy and adverse effects makes the classic and widely used classification system of TCs based upon potency out of date. Indeed, TCs with increasing potency have been characterised up to now, as a rule, by an increasing risk of adverse effects. Therefore, a classification system taking into major account the benefit/risk ratio seems particularly needed for clinical use in dermatology.

引用

页码：406 / 412

页数：7

共 56 条

[31]

Lesnik R.H., Mezick J.A., Capetola R., Et al., Topical all-trans retinoic acid prevents corticosteroid-induced skin atrophy without abrogating the anti-inflammatory effect, Journal of the American Academy of Dermatology, 21, pp. 186-190, (1989)

[32]

Maibach H.I., Stoughton R.B., Topical corticosteroids, Steroid therapy, (1975)

[33]

McKenzie A.W., Stoughton R.B., Method comparing percutaneous absorption of steroids, Archives of Dermatology, 88, pp. 608-610, (1962)

[34]

Meyer E., Smith E.W., Haigh J.M., Et al., Potency ranking of two new topical corticosteroid creams containing 0,1% desonide or 0,05 halometasone utilising human skin blanching assay, Arzneimittelforschung (Drug Res), 38, pp. 1840-1843, (1988)

[35]

Miller J.A., Monroe D.D., Topical corticosteroids: clinical pharmacology and therapeutic use, Drugs, 19, pp. 119-134, (1990)

[36]

Nilsson J.E., Gip L.J., Systemic effects of local treatment with high doses of potent corticosteroids in psoriasis, Acta DermatoVenereologica (Stockholm), 59, pp. 245-248, (1979)

[37]

Ortonne J.R., Clinical potential of topical corticosteroids, Drugs, 36, pp. 38-42, (1988)

[38]

Ortonne J.R., Safety aspects of topical methylprednisolone aceponate (MPA) treatment, Journal of Dermatological Treatment, 3, 2, pp. 21-25, (1992)

[39]

Parish L.C., Witkowsky J.A., Millikan L.E., Et al., The potency, efficacy, and usage of superpotent topical corticosteroids, International Journal of Dermatology, 29, pp. 709-710, (1990)

[40]

Phillips G.H., Locally active corticosteroids: structure-activity relationship, Mechanism of topical corticosteroid activity, pp. 1-6, (1976)

← 1 2 3 4 5 6 →